ArticleScientific reports2025
Mucosomes as next-generation drug carriers for treating mucus-resident bacterial infections and biofilms.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Non-specific Protein and Peptide Antibacterial Factors of Mammals.The protein journal · 2026Review
- Antibiotics release by hybrid bone scaffold: relationship between kinetic profiles and scaffold intrinsic features.Frontiers in bioengineering and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Deaths connected to bacterial infections are expected to outnumber those caused by cancer by 2050. Multiple advantages, including enhanced efficacy of the treatment, characterize the use of nanocarriers to deliver antibiotics. This work explores the use of mucosomes - intrinsically glycosylated mucin nanoparticles - to deliver ciprofloxacin to fight Pseudomonas aeruginosa and Staphylococcus aureus infections. Mucins are a family of glycoproteins representing the major non-aqueous component of human mucus and are known for actively interacting with bacteria, reducing their virulence, and limiting their aggregations. This study shows that these critical properties of mucin are preserved in mucosomes, enabling a strong synergy with the loaded antimicrobial drug. Empty mucosomes exert a bacteriostatic activity, inhibiting bacterial growth up to 70%. Ciprofloxacin-loaded mucosomes were able to decrease the minimum inhibitory concentration of ciprofloxacin against S. aureus by up to 50%. Mucosomes could prevent biofilm formation and disassemble well-established biofilms by reducing the biomass by up to 98%. Mucosomes further facilitated the transmucosal delivery of ciprofloxacin in a 3D mucus-mimicking model. These results, together with the possibility of freeze-drying and storing drug-loaded mucosomes without impairing their efficacy, suggest the suitability of this approach to tackle mucosal bacterial infections. Interestingly, this nanosystem has been shown to enhance the phagocytic action of blood in eradicating bacterial biofilms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.